MedTrace Logo

A Study of IBI363 in Subjects With Advanced Malignancies

NCT06468098 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 556

Last updated 2024-07-18

No results posted yet for this study

Summary

This is an open-label, multicenter Phase Ib study to evaluate the safety, tolerability, and efficacy of IBI363 in advanced malignancies patients

Conditions

  • Advanced Malignancies

Interventions

DRUG

IBI363 + chemotherapy

In this group, patients will receive IBI363 and chemotherapy

DRUG

IBI363 + Investigator's Choice SOC

In this group, patients will receive IBI363 and Investigator's Choice SOC

Sponsors & Collaborators

  • Innovent Biologics (Suzhou) Co. Ltd.

    lead INDUSTRY

Principal Investigators

  • tingbo Liang, M.D. · The First Affiliated Hospital ZJ University

  • xueli Bai, M.D. · The First Affiliated Hospital ZJ University

  • jianming Xu, M.D. · Chinese PLA General Hospital

  • shun Lu, M.D. · Shanghai Chest Hospita

  • tao Zhang, M.D. · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-15
Primary Completion
2025-06-30
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06468098 on ClinicalTrials.gov